Symptom characteristics and the development of tolerance with time in patients with indwelling double‐pigtail ureteric stents

Irani, Jacques; Siquier, J; Pires, Cleidismar R.; Lefebvre, O.; Doré, B.; Aubert, Jean‐François

doi:10.1046/j.1464-410x.1999.00154.x

Cited by 93 publications

(50 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Given this point, we used same stents, although we could also use different size of stents proportionate to the patients' length. Second, the stenting duration was different among the groups but it was not significant (p = 0.06); however, Irani et al (26) demonstrated that stent-related symptoms after some days remained unchanged. Third, we used the IPSS to evaluate urinary symptoms, but Joshi et al (27) have developed a specific tool for assessing stent-related symptoms which is named "ureteric stent symptoms questionnaire" (USSQ).…”

Section: Discussionmentioning

confidence: 87%

“…This study had some limitations. First, we applied stents with the same size and length; however, some studies have shown that the stent length is associated with stent-related symptoms (8), and others have revealed that it did not have any impact on stent discomforts (25,26). Given this point, we used same stents, although we could also use different size of stents proportionate to the patients' length.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Effects of Terazosin and Tolterodine on Ureteral Stent Related Symptoms: A Double-Blind Placebo-Controlled Randomized Clinical Trial

et al. 2013

View full text Add to dashboard Cite

Objective: To evaluate the effects of terazosin and tolterodine on ureteral stent discomfort. Materials and Methods: Of 163 patients assessed for eligibility, 104 patients were randomly assigned to receive placebo, 2 mg of terazosin twice daily, 2 mg of tolterodine daily, or both terazosin plus tolterodine during the stenting period. Prior to stenting and at stent removal, the International Prostate Symptom Score (IPSS), the IPSS quality of life (QoL) subscore and the Visual Analog Scale for Pain were determined. The patients also reported their analgesic use during the stenting period. Results: Ninety-four patients completed the study. We noted significant decreases in the total IPSS scores (p = 0.002), irritative subscore (p = 0.039), QoL (p = 0.001), flank pain (p = 0.013), voiding pain (p = 0.01) and amount of analgesics used (p = 0.02) in the groups. However, neither the obstructive subscore nor the suprapubic pain improved significantly (p = 0.251 and p = 0.522, respectively). The patients receiving terazosin plus tolterodine experienced significant reductions in the total IPSS, irritative symptoms, QoL, flank pain, voiding pain and decreased analgesics use compared with those patients receiving placebo. However, compared with placebo, terazosin monotherapy did not affect pain levels, and tolterodine monotherapy did not improve QoL, flank pain or analgesics use. Conclusions: Terazosin plus tolterodine improves ureteral stent-related complications, including irritative symptoms, the amount of analgesics used, QoL, flank pain and voiding pain but does not decrease obstructive symptoms or suprapubic pain. This trial was registered at www.clinicaltrials.gov as NCT01530243.

show abstract

Section: Discussionmentioning

confidence: 87%

Section: Discussionmentioning

confidence: 99%

Effects of Terazosin and Tolterodine on Ureteral Stent Related Symptoms: A Double-Blind Placebo-Controlled Randomized Clinical Trial

et al. 2013

View full text Add to dashboard Cite

show abstract

“…Both the interventions are associated with untoward symptoms and may have a negative impact on patients’ HRQoL. Ureteric stents are associated with various lower urinary tract symptoms and pain in the loin and bladder region of varying severity [3, 4, 5, 6, 7, 8]. These in turn may have an influence on patients’ general health [15].…”

Section: Discussionmentioning

confidence: 99%

“…The development of the questionnaires was based on a literature review, which also included guidance on the construction of the questionnaires, opinions of the urologists as well as nursing experience based on the day–to–day management of such patients [3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13]. For each group the questionnaire included a common validated single health index (two part EuroQol EQ–5D) as a generic measure [14]and an additional intervention–specific questionnaire.…”

Section: Methodsmentioning

confidence: 99%

Nephrostomy Tube or ‘JJ’ Ureteric Stent in Ureteric Obstruction: Assessment of Patient Perspectives Using Quality–of–Life Survey and Utility Analysis

et al. 2001

View full text Add to dashboard Cite

“…10,11 However this issue is controversial; there are some studies reporting that length and diameter of the stent does not significantly affect a patient's stent-related symptoms and quality of life. 12,13 Further prospective randomized studies are needed in this field. The stents were 26 to 28 cm in length in our study.…”

Section: Discussionmentioning

confidence: 99%

Effectiveness of medical treatment in overcoming the ureteral double-J stent related symptoms

Kuyumcuoğlu

Eryıldırım

Tuncer

et al. 2012

CUAJ

View full text Add to dashboard Cite

Background: We investigated whether the frequency of lower urinary tract symptoms (LUTS) increased in patients in whom double-J stents were applied. We also evaluated several medical therapy protocols to treat symptoms related with ureteral stents. Materials and Methods: A total of 108 patients, in whom unilateral double-j stent was applied during ureteral stone treatment, were included. Before the double-J stent was applied, all patients completed storage components of the "International Prostate Symptom Score" (IPSSs), quality of life components of the IPSS (IPSS-QOL) and "Overactive Bladder Questionnaire" (OABq) forms and scores were calculated. After the procedure, cases were randomized into 5 groups, an antiinflammatory was given to Group 1, spasmolytic to Group 2, anticholinergic to Group 3 and α-blocker to Group 4. No additional drug was given to Group 5 as this control group. During the fourth week of the procedure, IPSSs, IPSS-QOL and OABq forms were again completed and scores were compared with the previous ones. Results: When all the cases were evaluated, the IPSSs, IPSS-QOL and OABq scores of patients in whom the double-J stent was applied were statistically significantly higher the procedure. Compared to the control group, the cases where the double-J stent was applied showed a higher IPSSs, IPSS-QOL and OABq scores and none of the medical therapies could prevent this increase. Interpretation: The frequency of LUTS increased in cases where the ureteral stent was applied and discomfort continued as long as the stent stayed in the body. IntroductionCystoscopic intraluminal placement of ureteral stents has become a routine practice in urology. Ureteral stents preserve urine flow from the kidney to the bladder in cases of ureteral obstruction (intrinsic or extrincis). In patients with obvious ureteral obstruction, the placement of a ureteral stent will restart urine transport and protect the kidney from possible risks. The stents also prevent urine extravasation after an operation or trauma.One of the most preferred stents is the double-J stent with J-shaped ends on both sides. Ureteral double-j stents are generally placed for a temporary period. The duration of the stent may differ due to the reason of the application and the experience of the doctor. Although double-J stents are generally safe and well-tolerated, they have complications, such as pain, discomfort, urinary infection, recurrent obstruction, stent encrustation, stent fragmantation and stent migration. Their negative effects on quality of life and sexual functions have also been emphasized by some researchers.1,2 Research is ongoing in developing and validating questionnaires on symptoms related to ureteral stents and the effects of these symptoms on daily life.A way to reduce symptoms related with stents might be to alter the design and material of the stents. Researchers continue to study the effect of several medical therapies on reducing the negative symptoms which affect quality of life. 1,3 In this study, we investigated whet...

show abstract

Symptom characteristics and the development of tolerance with time in patients with indwelling double‐pigtail ureteric stents

Cited by 93 publications

References 7 publications

Effects of Terazosin and Tolterodine on Ureteral Stent Related Symptoms: A Double-Blind Placebo-Controlled Randomized Clinical Trial

Effects of Terazosin and Tolterodine on Ureteral Stent Related Symptoms: A Double-Blind Placebo-Controlled Randomized Clinical Trial

Nephrostomy Tube or ‘JJ’ Ureteric Stent in Ureteric Obstruction: Assessment of Patient Perspectives Using Quality–of–Life Survey and Utility Analysis

Effectiveness of medical treatment in overcoming the ureteral double-J stent related symptoms

Contact Info

Product

Resources

About

Symptom characteristics and the development of tolerance with time in patients with indwelling double‐pigtail ureteric stents

Cited by 93 publications

References 7 publications

Effects of Terazosin and Tolterodine on Ureteral Stent Related Symptoms: A Double-Blind Placebo-Controlled Randomized Clinical Trial

Effects of Terazosin and Tolterodine on Ureteral Stent Related Symptoms: A Double-Blind Placebo-Controlled Randomized Clinical Trial

Nephrostomy Tube or &lsquo;JJ&rsquo; Ureteric Stent in Ureteric Obstruction: Assessment of Patient Perspectives Using Quality&ndash;of&ndash;Life Survey and Utility Analysis

Effectiveness of medical treatment in overcoming the ureteral double-J stent related symptoms

Contact Info

Product

Resources

About

Nephrostomy Tube or ‘JJ’ Ureteric Stent in Ureteric Obstruction: Assessment of Patient Perspectives Using Quality–of–Life Survey and Utility Analysis